Three Purdue scientists of different expertise joined forces to lead a research team – Shriram Ramanathan, professor of materials engineering; Hyowon “Hugh” Lee, assistant professor of biomedical engineering; and Alexander Chubykin, assistant professor of biological sciences.
Chubykin and Lee had been working together on new ways to sense neurotransmitters in the brain, seeking materials that could trace these chemicals with greater sensitivity and speed. Ramanathan had been working separately on just such a material for years, discovering doping methods for perovskites to be more sensitive to certain chemicals. This material – a perovskite nickelate coated with a nafion layer – turned out to be just what his colleagues were seeking. Through a series of tests, the team discovered that this material is perfect for tracking glutamate, a chemical that the brain’s nerve cells use to communicate with other cells.
Glutamate, one of the most abundant amino acids in the body, is used by every major brain function and is one of the primary molecules the brain uses to send and receive information for control of motor function, learning and remembering. Tracking its presence or absence in certain areas of the brain could lead to more insight into autism and other disorders.
“Different forms of autism create different changes to glutamate levels in the brain, and understanding them is important,” Chubykin said. “Neural degeneration is marked by a decrease in glutamate. If we can measure that better, it will be very exciting.”
Several candidates for glutamate biosensors have been developed in the past, but this new material greatly improves both the sensitivity level and the response time. To understand the composition and structure of the new material, crystals of it were grown and analyzed at the Center for Nanoscale Materials (CNM), and X-ray analysis of the material was conducted at the Advanced Photon Source (APS). Both CNM and APS are U.S. Department of Energy Office of Science User Facilities at Argonne.
Ilke Arslan, the director of CNM, is a co-author on the paper. She and her team were involved in characterizing the perovskite nickelate thin films of this material by imaging them at the atomic scale using CNM’s powerful electron microscopes.
“This interdisciplinary collaboration is a wonderful demonstration of how materials science and characterization at the atomic scale can link with biomedical engineering and neuroscience to lead to new breakthroughs that will benefit humankind,” Arslan said.
X-ray measurements were carried out on two APS beamlines – 33-ID-D and 29-ID-D, both operated by Argonne’s X-ray Science Division (XSD). The powerful X-rays of the APS allowed for precise imaging of the reactions within the material to the presence of various doses of glutamate.
Fanny Rodolakis, an XSD physicist, worked with the Purdue team at 29-ID-D. “They know their samples very well and are able to fully characterize their macroscopic properties, but they don’t have the tools to look at them on a microscopic, quantum level,” Rodolakis said. “You need a light source like the APS, so you can tune the energy of the X-ray beams to see how the chemical treatments affect the material on this level. They have the perfect samples, and we have the perfect giant toolbox to help them.”
The glutamate-sensing properties of this material were tested in brain slices, but the most crucial test was with live mice – what scientists refer to as in vivo, or performed in a living organism.
“We need ways to understand the brain while it is alive, because our usual characterization involves looking at brain slices post-mortem,” Arslan said.
In Chubykin’s lab at Purdue, the new material was implanted into the visual cortex of a mouse under anesthesia, and when the mouse awoke, scientists were able to track its responses to visual stimuli.
“We showed the mouse pictures,” Lee said. “We showed it a checkerboard pattern, lines and bars, images that the brain responds to most.”
The results showed increased sensitivity and faster response time than other glutamate-sensing materials. The next step, Ramanathan said, is to create smaller microneedles to track glutamate in specific sections of the brain, working with more specific stimuli. This, he said, opens up more possibilities to sense different types of neurotransmitters.
For Ramanathan, this material also is a step toward machines that can interface with the human brain and possibly read and react to sensory information. He calls this the holy grail of neural links.
With such promising results, this team intends to keep its association going.
“That’s the beauty of this effort,” Lee said. “I had no idea about the existence of this type of material. This has given us all new tools for collaboration and allowed us to create better tools for studying the mechanism of neurological disorders.”